All In Biotech

Drug Trial Radar · NCT03845582

Phase 2/3 Study of ALK-001 in Geographic Atrophy

A Phase 2/3 Multicenter, Randomized, Double-masked, Parallel-group, Placebo-controlled Study to Investigate the Safety, Pharmacokinetics, Tolerability, and Efficacy of ALK-001 in Geographic Atrophy Secondary to Age-related Macular Degeneration

Last checked: Nov 19, 2026Latest source record: Nov 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

200

Actual

Start

May 7, 2019

Primary completion

Jul 25, 2023

Study completion Jun 30, 2024

Sponsor

Lead sponsor
Alkeus Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Feb 19, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a double-masked, multicenter, randomized, placebo-controlled clinical trial, evaluating the efficacy and safety of ALK-001 in participants with Geographic Atrophy (GA) secondary to age-related macular degeneration (AMD). Up to 200 participants will receive ALK-001 while up to 100 participants will receive a placebo.

Conditions

  • Geographic Atrophy
  • Age Related Macular Degeneration
  • AMD
  • Atrophy, Geographic

Interventions

  • ALK-001 oral capsuleDrug

    Daily administration for 24 months

  • Placebo oral capsuleDrug

    Daily administration for 24 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Growth Rate of GA Lesions, as Assessed by Fundus Autofluorescence (FAF)Time frame: Baseline to 24 months

Locations

24 sites in 1 country. Site status is shown where the registry gives one.

  • Alkeus Site

    Phoenix, Arizona

  • Alkeus Site

    Beverly Hills, California

  • Alkeus Site

    Lakewood, Colorado

  • Alkeus Site

    Clearwater, Florida

  • Alkeus Site

    Fort Myers, Florida

  • Alkeus Site

    Gainesville, Florida

  • Alkeus Site

    Tampa, Florida

  • Alkeus Site

    Winter Haven, Florida

  • Alkeus Site

    Bloomington, Illinois

  • Alkeus Site

    Lexington, Kentucky

  • Alkeus Site

    Chevy Chase, Maryland

  • Alkeus Site

    Worcester, Massachusetts

  • Alkeus Site

    Grand Rapids, Michigan

  • Alkeus Site

    Edina, Minnesota

  • Alkeus Site

    Northfield, New Jersey

  • Alkeus Site

    Great Neck, New York

  • Alkeus Site

    Hauppauge, New York

  • Alkeus Site

    Cleveland, Ohio

  • Alkeus Site

    Ashland, Oregon

  • Alkeus Site

    Houston, Texas

  • Alkeus Site-1

    San Antonio, Texas

  • Alkeus Site-2

    San Antonio, Texas

  • Alkeus Site

    Fairfax, Virginia

  • Alkeus Site

    Silverdale, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.